25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Employment Law Update - On 4 July 2019, the Fair Work Commission announced changes to the annualis...
Read More >
On August 12, 2019, the National Labor Relations Board (NLRB) will publish a notice of proposed rule...
Read More >
While few deals are challenged in Canada, national security reviews are becoming more common and com...
Read More >
In late 2019, the Northern District of Georgia (Atlanta federal court) addressed the duties owed whe...
Read More >
The Digitalization Act, which entered into force on January 19, 2021, substantially extends the scop...
Read More >
“Operation Pay Dirt” was a joint investigation by the Suffolk County District Attorney’s Office, ...
Read More >